Update on novel therapeutics for primary CNS lymphoma Review
| Authors: | Schaff, L. R.; Grommes, C. |
| Review Title: | Update on novel therapeutics for primary CNS lymphoma |
| Abstract: | Primary central nervous system lymphoma (PCNSL) is a rare lymphoma isolated to the central nervous system or vitreoretinal space. Standard treatment consists of cytotoxic methotrex-ate‐based chemotherapy, with or without radiation. Despite high rates of response, relapse is com-mon, highlighting the need for novel therapeutic approaches. Recent advances in the understanding of PCNSL have elucidated mechanisms of pathogenesis and resistance including activation of the B‐cell receptor and mammalian target of rapamycin pathways. Novel treatment strategies such as the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, phosphatidylinositol‐3 kinase (PI3K) inhibi-tors, and immunomodulatory drugs are promising. Increasingly, evidence suggests immune eva-sion plays a role in PCNSL pathogenesis and several immunotherapeutic strategies including check-point inhibition and targeted chimeric antigen receptor T (CAR‐T) cells are under investigation. This review provides a discussion on the challenges in development of targeted therapeutic strate-gies, an update on recent treatment advances, and offers a look toward ongoing clinical studies. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. |
| Keywords: | methotrexate; novel therapies; novel therapeutics; pcnsl; cns lymphoma |
| Journal Title: | Cancers |
| Volume: | 13 |
| Issue: | 21 |
| ISSN: | 2072-6694 |
| Publisher: | MDPI |
| Date Published: | 2021-11-01 |
| Start Page: | 5372 |
| Language: | English |
| DOI: | 10.3390/cancers13215372 |
| PROVIDER: | scopus |
| PMCID: | PMC8582401 |
| PUBMED: | 34771535 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 December 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work